Kalos Management, Inc. Innoviva, Inc. Transaction History

Kalos Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Jun 21, 2022	SELL	$15.39 - $20.25 $2.35 Million - $3.1 Million	-152,957 Closed	0 $0
Q4 2021 Feb 03, 2022	BUY	$15.91 - $18.72 $200,927 - $236,414	12,629 Added 9.0%	152,957 $2.83 Million
Q3 2021 Nov 10, 2021	SELL	$13.06 - $17.24 $176,296 - $232,722	-13,499 Reduced 8.78%	140,328 $2.59 Million
Q2 2021 Aug 11, 2021	BUY	$11.45 - $13.96 $64,211 - $78,287	5,608 Added 3.78%	153,827 $2.33 Million
Q1 2021 May 13, 2021	BUY	$11.06 - $12.87 $517,519 - $602,213	46,792 Added 46.13%	148,219 $1.8 Million
Q4 2020 Feb 11, 2021	BUY	$9.33 - $12.48 $946,313 - $1.27 Million	101,427 New	101,427 $1.25 Million

227

78.9M

37.6K

300

Ticker INVA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,706,000
Market Cap $1.24B
Description
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...

Get notified when there are updates to the investment portfolio of Kalos Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Kalos Management, Inc. with notifications on news.